A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : topo IIalpha / topoisomerase IIalpha

[Related PubMed/MEDLINE]
Total Number of Papers: 248
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   topo IIalpha  (>> Co-occurring Abbreviation)
Long Form:   topoisomerase IIalpha
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 Predictive factors of pathological response to neoadjuvant chemotherapy in patients with breast cancer. BC, NACT, pCR, TNBC
2020 Topoisomerase IIalpha prevents ultrafine anaphase bridges by two mechanisms. dsDNA, UFBs
2019 Combination value of diffusion-weighted imaging and dynamic susceptibility contrast-enhanced MRI in astrocytoma grading and correlation with GFAP, Topoisomerase IIalpha and MGMT. ADC, DSC, DWI, GFAP, IHC, MGMT, MRI, rCBV
2019 DNA Damage and Perturbed Topoisomerase IIalpha as a Target of 1,4-Benzoquinone Toxicity in Murine Fetal Liver Cells. 4-HNE, BQ
2019 Expressions of Topo IIalpha and Ki67 in breast cancer and its clinicopathologic features and prognosis. TTP
2019 Impact of Topoisomerase IIalpha, PTEN, ABCC1/MRP1, and KI67 on triple-negative breast cancer patients treated with neoadjuvant chemotherapy. LI, NAC, TNBC
2019 Structural and Metal Ion Effects on Human Topoisomerase IIalpha Inhibition by alpha-(N)-Heterocyclic Thiosemicarbazones. TSC
2018 A new phenolic series of indenopyridinone as topoisomerase inhibitors: Design, synthesis, and structure-activity relationships. ---
2018 Association between Twist and multidrug resistance gene-associated proteins in Taxol-resistant MCF-7 cells and a 293 cell model of Twist overexpression. LRP, MDR, MRP, P-gp
10  2018 Mitotic Phosphorylation of SENP3 Regulates DeSUMOylation of Chromosome-Associated Proteins and Chromosome Stability. ---
11  2018 Synthesis and SAR study of new hydroxy and chloro-substituted 2,4-diphenyl 5H-chromeno[4,3-b]pyridines as selective topoisomerase IIalpha-targeting anticancer agents. SAR
12  2017 Design, synthesis, and identification of a novel napthalamide-isoselenocyanate compound NISC-6 as a dual Topoisomerase-IIalpha and Akt pathway inhibitor, and evaluation of its anti-melanoma activity. NISC, NSU
13  2017 Fluorescein hydrazones: A series of novel non-intercalative topoisomerase IIalpha catalytic inhibitors induce G1 arrest and apoptosis in breast and colon cancer cells. topo I
14  2017 Modulation of topoisomerase IIalpha expression and chemosensitivity through targeted inhibition of NF-Y:DNA binding by a diamino p-anisyl-benzimidazole (Hx) polyamide. ICB2
15  2017 Non-Catalytic Roles of the Topoisomerase IIalpha C-Terminal Domain. CTD, SUMO
16  2017 Novel 2-aryl-4-(4'-hydroxyphenyl)-5H-indeno[1,2-b]pyridines as potent DNA non-intercalative topoisomerase catalytic inhibitors. ---
17  2017 Significance of Tumor-Infiltrating Lymphocytes and the Expression of Topoisomerase IIalpha in the Prediction of the Clinical Outcome of Patients with Triple-Negative Breast Cancer after Taxane-Anthracycline-Based Neoadjuvant Chemotherapy. DFS, NAC, OS, pCR, TILs, TNBC
18  2017 Smurf2-Mediated Stabilization of DNA Topoisomerase IIalpha Controls Genomic Integrity. ---
19  2016 DNA Topoisomerase IIalpha contributes to the early steps of adipogenesis in 3T3-L1 cells. MCE, topo
20  2016 DNA-binding activity of rat DNA topoisomerase II alpha C-terminal domain contributes to efficient DNA catenation in vitro. CTD, WT
21  2016 Histone Deacetylase Inhibitors Trichostatin A and MCP30 Relieve Benzene-Induced Hematotoxicity via Restoring Topoisomerase IIalpha. HDAC, TSA
22  2016 Perichromosomal protein Ki67 supports mitotic chromosome architecture. ---
23  2016 PICH promotes mitotic chromosome segregation: Identification of a novel role in rDNA disjunction. UFBs
24  2016 Quinolino[3,4-b]quinoxalines and pyridazino[4,3-c]quinoline derivatives: Synthesis, inhibition of topoisomerase IIalpha, G-quadruplex binding and cytotoxic properties. ---
25  2016 Topoisomerase IIalpha mediates TCF-dependent epithelial-mesenchymal transition in colon cancer. ChIP, Co-IP, CRCs, EMT, MDR, neo, TCF, TIC, WREs
26  2015 A multifactorial 'Consensus Signature' by in silico analysis to predict response to neoadjuvant anthracycline-based chemotherapy in triple-negative breast cancer. ConSig, mRNA, OR, pCR, TNBC
27  2015 Assessment of cell proliferation in renal cell carcinoma using dual-phase 18F-fluorodeoxyglucose PET/CT. 18F-FDG, MCM2, RCC, RI, SUV1
28  2015 beta-Elemene Inhibits Cell Proliferation by Regulating the Expression and Activity of Topoisomerases I and IIalpha in Human Hepatocarcinoma HepG-2 Cells. beta-ELE, kDNA, topo I
29  2015 CIP-36, a novel topoisomerase II-targeting agent, induces the apoptosis of multidrug-resistant cancer cells in vitro. MDR
30  2015 Cytotoxic and natural killer cell stimulatory constituents of Phyllanthus songboiensis. IL-12, NK
31  2015 Fibroblast growth factor receptor 4 protein expression and clinicopathological features in gastric cancer. FFPE, FGFR4, GC, IHC
32  2015 Hydroxylated 2,4-diphenyl indenopyridine derivatives as a selective non-intercalative topoisomerase IIalpha catalytic inhibitor. ---
33  2015 Nuclear Localization and Gene Expression Modulation by a Fluorescent Sequence-Selective p-Anisyl-benzimidazolecarboxamido Imidazole-Pyrrole Polyamide. ICB2
34  2015 Selective killing of G2 decatenation checkpoint defective colon cancer cells by catalytic topoisomerase II inhibitor. ---
35  2015 Sensitivity of gastric cancer cells to chemotherapy drugs in elderly patients and its correlation with cyclooxygenase-2 expression. 5-FU, COX-2, GST-pi, HCPT, IR, MDR, MMC, MTT, P-gp, PTX, VCR
36  2015 SUMOylation regulates polo-like kinase 1-interacting checkpoint helicase (PICH) during mitosis. PARP1, PICH, SUMO
37  2015 Topoisomerase II regulates the maintenance of DNA methylation. ---
39  2014 Associations between clinicopathological prognostic factors and pAkt, pMAPK and topoisomerase II expression in breast cancer. MAPK, p-Akt, pMAPK
40  2014 BCL-2, topoisomerase IIalpha, microvessel density and prognosis of early advanced breast cancer patients after adjuvant anthracycline-based chemotherapy. BC, Bcl-2, DFS, ER, MVD, PgR
41  2014 CS1 is a novel topoisomerase IIalpha inhibitor with favorable drug resistance profiles. topo II
42  2014 Effect of nitric oxide synthase on multiple drug resistance is related to Wnt signaling in non-small cell lung cancer. DKK1, GST-pi, MDR, NSCLC, P-gp, SFRP1
43  2014 Expression of DNA topoisomerase II-alpha: Clinical significance in laryngeal carcinoma. ---
44  2014 Granzyme M targets topoisomerase II alpha to trigger cell cycle arrest and caspase-dependent apoptosis. GrM
45  2014 Induction of apoptosis in cholangiocarcinoma by an andrographolide analogue is mediated through topoisomerase II alpha inhibition. CCA, IC50
46  2014 Nucleo-cytoplasmic transport as a therapeutic target of cancer. SINE
47  2014 Prognostic importance of survivin, Ki-67, and topoisomerase IIalpha in ovarian carcinoma. EOC
48  2014 Smc5/6-mediated regulation of replication progression contributes to chromosome assembly during mitosis in human cells. SMC
49  2014 TopoIIalpha prevents telomere fragility and formation of ultra thin DNA bridges during mitosis through TRF1-dependent binding to telomeres. SAC, UFB
50  2014 Topoisomerase IIalpha as a prognostic factor in pituitary tumors. ACTH
51  2014 [Topoisomerase IIa expression in correlation with clinical and morphological parameters and proliferation (based on argyrophilic proteins of nucleolar organizer regions and Ki-67 antigen) in lung adenocarcinoma]. Ag-NOR
52  2013 (-)-Xanthatin induces the prolonged expression of c-Fos through an N-acetyl-L-cysteine (NAC)-sensitive mechanism in human breast cancer MDA-MB-231 cells. NAC, ROS
53  2013 (-)-Xanthatin up-regulation of the GADD45gamma tumor suppressor gene in MDA-MB-231 breast cancer cells: role of topoisomerase IIalpha inhibition and reactive oxygen species. GADD45gamma, ROS
54  2013 3-(3-Butylamino-2-hydroxy-propoxy)-1-hydroxy-xanthen-9-one acts as a topoisomerase IIalpha catalytic inhibitor with low DNA damage. ---
55  2013 A novel chromatin tether domain controls topoisomerase IIalpha dynamics and mitotic chromosome formation. ChT
56  2013 CRM1 Inhibition Sensitizes Drug Resistant Human Myeloma Cells to Topoisomerase II and Proteasome Inhibitors both In Vitro and Ex Vivo. CRM1, MM, SINE
57  2013 Cyclin D1 in invasive breast carcinoma: favourable prognostic significance in unselected patients and within subgroups with an aggressive phenotype. PR
58  2013 Differential diagnosis of reactive mesothelial cells and malignant mesothelioma cells using the cell proliferation markers minichromosome maintenance protein 7, geminin, topoisomerase II alpha and Ki-67. LIs, MCM7
59  2013 DNA topoisomerase IIalpha controls replication origin cluster licensing and firing time in Xenopus egg extracts. ---
60  2013 Induction of DNA damage and ATF3 by retigeric acid B, a novel topoisomerase II inhibitor, promotes apoptosis in prostate cancer cells. ATF3, PCa, RB
61  2013 P53, MAPK, topoisomerase II alpha and Ki67 immunohistochemical expression and KRAS/BRAF mutation in ovarian serous carcinomas. OSCs
62  2013 Treatment with gefitinib or lapatinib induces drug resistance through downregulation of topoisomerase IIalpha expression. DSB, EGFR, TKI
63  2012 Correlations of TOP2A gene aberrations and expression of topoisomerase IIalpha protein and TOP2A mRNA expression in primary breast cancer: a retrospective study of 86 cases using fluorescence in situ hybridization and immunohistochemistry. ---
64  2012 DNA topoisomerase II alpha: a favorable prognostic factor in colorectal caner. ---
65  2012 Glucose-regulated protein 75 overexpression attenuates ionizing radiation-mediated injury in PC12 cells by inducing the expression of topoisomerase IIalpha. GRP75, HSP70, IR
66  2012 Heterogeneity of COX-2 and multidrug resistance between primary tumors and regional lymph node metastases of gastric cancer. COX-2, GST-pi, MDR, P-gp
67  2012 Impacts and predictors of cytotoxic anticancer agents in different breast cancer subtypes. CK, EGFR, QpCR
68  2012 Quantitative analysis of topoisomerase II alpha and evaluation of its effects on cell proliferation and apoptosis in glioblastoma cancer stem cells. CSCs
69  2012 The association between the p53/topoisomerase I and p53/ topoisomerase IIalpha immunophenotypes and the progression of ovarian carcinomas. topo I
70  2012 The value of expression of EGFR, telomerase and topoisomerase IIalpha in malignant effusion smears before and after chemotherapy. EGFR
71  2012 Topo IIalpha gene alterations correlated with survival in patients with diffuse large B-cell lymphoma. DLBCL, GCB, non-GCB, OS, PFS
72  2012 Topoisomerase IIalpha levels and G2 radiosensitivity in T-lymphocytes of women presenting with breast cancer. PHA
73  2012 [Auto-analysis of immunohistochemical findings for breast cancer using specified software and virtual microscopy]. ER, HER2, MTs, PgR
74  2011 D11, a novel glycosylated diphyllin derivative, exhibits potent anticancer activity by targeting topoisomerase IIalpha. ---
75  2011 Decreased topoisomerase IIalpha expression and altered histone and regulatory factors of topoisomerase IIalpha promoter in patients with chronic benzene poisoning. ChIP
76  2011 Expression of P-gp, MRP, LRP, GST-pi and TopoIIalpha and intrinsic resistance in human lung cancer cell lines. LRP, MRP, P-gp
77  2011 Geminin overexpression prevents the completion of topoisomerase IIalpha chromosome decatenation, leading to aneuploidy in human mammary epithelial cells. CDC7, CKIepsilon, HME
78  2011 Prognostic potential of topoisomerase IIalpha and HER2 in a retrospective analysis of early advanced breast cancer patients treated with adjuvant anthracycline chemotherapy. CK, DFS, ER, FISH, HER2, PgR
79  2011 Spotlight on geminin. ---
80  2011 Tissue microarray analysis of topoisomerase IIalpha protein in gastric adenocarcinomas: histogenetic and prognostic implications. ---
81  2011 Unprecedented citrinin trimer tricitinol B functions as a novel topoisomerase IIalpha inhibitor. ---
82  2011 [Topoisomerase IIalpha activity and tumor cell proliferation level from the degree of bromodeoxyuridine label in uterine body leiomyosarcoma]. BrdU, LM, UBL, UM
83  2010 Metnase promotes restart and repair of stalled and collapsed replication forks. NHEJ
84  2010 PIASy-dependent SUMOylation regulates DNA topoisomerase IIalpha activity. Lys660
85  2010 Significance of cell proliferation markers (Minichromosome maintenance protein 7, topoisomerase IIalpha and Ki-67) in cavital fluid cytology: can we differentiate reactive mesothelial cells from malignant cells? MCM7
86  2010 Targeting the ICB2 site of the topoisomerase IIalpha promoter with a formamido-pyrrole-imidazole-pyrrole H-pin polyamide. ---
87  2010 TOPOIIalpha and HER-2/neu overexpression/amplification in Barrett's oesophagus, dysplasia and adenocarcinoma. ADC, BO, FISH
88  2010 Topoisomerase IIalpha binding domains of adenomatous polyposis coli influence cell cycle progression and aneuploidy. APC
89  2010 Topoisomerase IIalpha maintains genomic stability through decatenation G(2) checkpoint signaling. ---
90  2010 [Effect of hydroquinone on expression of topoisomerase enzyme IIalpha in human bone marrow mononuclear cells]. ChIP, HQ
91  2010 [Relationship of cyclooxygenase-2 and multidrug resistance associated factors to chemosensitivities in gastrointestinal carcinomas]. COX-2, GST-pi, MTT, P-gp
92  2009 A phase II trial of a neoadjuvant platinum regimen for locally advanced breast cancer: pathologic response, long-term follow-up, and correlation with biomarkers. ER, LABC, pCR
93  2009 Analysis of SUMOylation of topoisomerase IIalpha with Xenopus egg extracts. SUMO, XEE
94  2009 Differential expression of topoisomerase IIalpha protein in salivary gland carcinomas: histogenetic and prognostic implications. ---
95  2009 Genistein inhibition of topoisomerase IIalpha expression participated by Sp1 and Sp3 in HeLa cell. ---
96  2009 HMGB1 and HMGB2 proteins up-regulate cellular expression of human topoisomerase IIalpha. ---
97  2009 Human multiple myeloma cells are sensitized to topoisomerase II inhibitors by CRM1 inhibition. siRNA
98  2009 Level of DNA topoisomerase IIalpha mRNA predicts the treatment response of relapsed acute leukemic patients. ---
99  2009 Metnase mediates chromosome decatenation in acute leukemia cells. AML
100  2009 Metnase mediates resistance to topoisomerase II inhibitors in breast cancer cells. ---